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Objectives. We evaluated C-reactive protein (CRP) alone and in
conjunction with a rapid qualitative assay for cardiac-specific
troponin T (cTnT) for predicting 14-day mortality in patients with
unstable angina or non-Q wave myocardial infarction (NQMI).
Background. Elevated CRP has been found to correlate with
higher risk for cardiac events in patients with coronary disease.
Methods. At enrollment into the Thrombolysis in Myocardial
Infarction (TIMI) 11A trial, a dose-ranging trial of enoxaparin for
unstable angina and NQMI, serum was obtained for CRP mea-
surement and rapid cTnT assay.
Results. Quantitative CRP and rapid cTnT assays were per-
formed in all patients. CRP was higher among patients who died
than in survivors (7.2 vs. 1.3 mg/dl, p 5 0.0038). The probability
of a positive rapid cTnT assay rose with increasing CRP concen-
tration (p < 0.0001). Among patients with a negative rapid cTnT
assay, the mortality rate was higher among patients with CRP
>21.55 mg/dl (5.80% vs. 0.36%, p 5 0.006). Patients with both an
early positive rapid cTnT assay (<210 min until assay positive) and
CRP >21.55 mg/dl had the highest mortality, followed by those
with either CRP >21.55 mg/dl or an early positive rapid cTnT
assay, whereas patients with both a negative rapid cTnT assay and
CRP <1.55 mg/dl were at very low risk (9.10% vs. 4.65% vs. 0.36%,
p 5 0.0003).
Conclusions. Elevated CRP at presentation in patients with
unstable angina or NQMI is correlated with increased 14-day
mortality, even in patients with a negative rapid cTnT assay.
Quantitative CRP and a rapid cTnT assay provide complementary
information for stratifying patients with regard to mortality risk.
(J Am Coll Cardiol 1998;31:1460–5)
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As our understanding of the pathogenesis of atherosclerotic
heart disease has evolved, the contribution of inflammation to
this process has attained increasing recognition (1–5). Several
of the acute-phase proteins, which serve as nonspecific markers
of the human inflammatory response, have been found to be
elevated across the clinical spectrum of atherosclerotic coro-
nary artery disease (6–14). Furthermore, increased concentra-
tions of the acute-phase reactant C-reactive protein (CRP)
appear to be predictive of higher risk for long-term cardiovas-
cular morbidity/mortality in patients with both stable and
unstable angina, as well as in asymptomatic patients at risk for
coronary artery disease (CAD) (15–18). This potential predic-
tive capacity of CRP warrants further evaluation alone and in
conjunction with established serum cardiac markers.
Cardiac-specific troponin T (cTnT), a subunit of the tropo-
nin regulatory complex in cardiac myocytes, is now well
recognized as a more sensitive and specific marker of myocar-
dial necrosis than creatine kinase and its MB isoenzyme.
Elevation of serum cTnT has been shown (19–23) to identify
patients with acute coronary syndromes at increased risk for
adverse clinical outcomes. Previous investigations of cTnT
(19–23) have demonstrated the prognostic value to be most
evident when specimens are collected .6 h after the onset of
ischemic symptoms. In a study of patients with severe unstable
angina with no increase in cTnT, Liuzzi et al. (24) observed
that an elevation of CRP above a threshold value of 0.3 mg/dl
was associated with a trend toward increased adverse clinical
outcomes, including major cardiac events, recurrent ischemia
and a prolonged hospital stay. A more recent analysis of data
collected in a large prospective European study of patients
with angina (18) has corroborated the predictive value of CRP
for major cardiac events; however, no data on cTnT were
provided in that report. In a recent report of a substudy in the
Thrombolysis in Myocardial Infarction (TIMI) 11A trial (25),
we demonstrated that a positive rapid bedside assay for cTnT
identifies those patients with unstable angina and non-Q wave
myocardial infarction (NQMI) at higher risk for adverse
clinical events. Furthermore, stratification of patients by time
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to development of a positive rapid assay identifies those
patients at highest risk of death (25). We now extend our
analysis of the patients enrolled in TIMI 11A. To define
further the prognostic information offered by CRP in acute
coronary syndromes, we evaluated the ability of CRP alone
and in conjunction with a rapid bedside assay for cTnT,
performed from simultaneous samples drawn at least 6 h after
symptom onset, to predict 14-day mortality in a cohort of
patients admitted to the hospital with unstable angina or
NQMI.
Methods
Patients. Men and women admitted with unstable angina
or NQMI and enrolled in the TIMI 11A trial at any one of the
45 participating centers were eligible for this serum marker
substudy. The TIMI 11A trial was an open-label dose-ranging
study of the low molecular weight heparin enoxaparin in
patients with evidence of ischemic heart disease presenting
with unstable angina or NQMI within the previous week,
defined as one of the following: rest angina of at least 5 min in
duration; new-onset angina of at least Canadian Cardiovascu-
lar Class III severity, with onset within 2 months of presenta-
tion; or previously diagnosed angina that became distinctly
more frequent, longer in duration or lower in threshold. To
support the presence of ischemic heart disease, patients must
have met at least one of the following criteria: a history of
typical myocardial ischemic-type discomfort; electrocardio-
graphic changes (ST segment deviation or T wave inversion, or
both) in association with ischemic discomfort; a history of
previous myocardial infarction (MI); a previous positive exer-
cise tolerance test; previous coronary artery bypass graft
surgery (CABG) or percutaneous transluminal coronary an-
gioplasty or a previous coronary angiogram showing 50%
stenosis of a major epicardial coronary vessel (26). Patients
with an evolving Q wave MI or thrombolytic therapy within
24 h before randomization, CABG within the previous 2
months or other serious illness (active cancer, significant
hepatic or renal dysfunction) were excluded. Other exclusion
criteria included contraindications to anticoagulation; ongoing
indication for long-term, continuous anticoagulation; or his-
tory of heparin-induced thrombocytopenia. Patients received
one of two weight-based doses of subcutaneous enoxaparin
plus aspirin administered in-hospital for a minimum of 48 h
and then continued receiving a fixed dose of subcutaneous
enoxaparin every 12 h, for a total treatment period of 2 weeks,
after which each patient’s clinical status was ascertained (26).
Blood sampling and measurement of serum markers. The
serum marker protocol specified that a serum specimen be
drawn at enrollment for the quantitative assessment of CRP.
The serum specimens were stored at 220°C or colder until
shipped to a core laboratory (Clinical Chemistry Laboratory,
Children’s Hospital, Boston, Massachusetts), where all sam-
ples were assayed by a single operator (D.L.W.) in blinded
manner as to patient treatment and outcome. Quantitative
serum CRP (N Latex CRP mono) determination was per-
formed with the Behring BN II Nephelometer (Behring Diag-
nostics). In this assay, polystyrene beads coated with mouse
monoclonal antibodies bind CRP present in the serum sample,
and form aggregates. The intensity of scattered light is propor-
tional to the size of the aggregates and thus reflects the
concentration of CRP present in the sample. The sensitivity of
the assay is 0.01 mg/dl, and reproducibility around concentra-
tions of 0.05, 5.5 and 13.8 mg/dl is 5.5, 2.9 and 3.6%, respec-
tively. Performance of this assay in the core laboratory in
serum obtained from 104 healthy adult blood donors demon-
strated a mean CRP of 0.215 mg/dl and a 99th percentile value
of 1.55 mg/dl. The value for the 99th percentile for control
serum was determined with the same instrument/assay used for
serum CRP measurement in each of the patient samples
analyzed in the study and was subsequently used as the CRP
threshold for the outcomes analysis.
In addition, a rapid bedside qualitative assay for cTnT was
performed at enrollment at each site by placing 150 ml of whole
blood in a specimen well where cTnT reacts with two mono-
clonal antibodies. The cTnT in the patient’s blood binds to the
two antibodies and forms a sandwich that flows along a
glass-fiber fleece toward the read zone. The immune com-
plexes are immobilized in the read zone by an interaction
between streptavadin and the biotinylated antibody, leading to
production of a purplish-red line in the read zone (27,28). The
intensity of the color and speed with which it develops corre-
late with the concentration of cTnT in the patient’s blood (27).
The detection limit of this version of the assay is 0.2 ng/ml of
cTnT. The test was read as either positive (red line appeared
within 20 min) or negative. Positive results were further
categorized as to whether the red line appeared within #10 or
.10 min, with an early positive result (i.e., at #10 min)
reflecting higher concentrations of cTnT (25).
Statistical analysis. The CRP and cTnT data were merged
with the main TIMI 11A clinical database, and analyses were
performed at COVANCE. To adequately assess the perfor-
mance of CRP and the rapid cTnT assay simultaneously, it was
required that patients included in the analysis have complete
information regarding both CRP and rapid cTnT status, in-
cluding the time to positivity of the rapid assay. In addition, on
the basis of previous experience with cardiac-specific tro-
ponins, which has shown diminished sensitivity in patients
presenting ,6 h after the onset of ischemic symptoms, patients
who had serum markers drawn ,6 h after symptom onset were
not included. Statistical comparison of baseline characteristics
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CAD 5 coronary artery disease
CI 5 confidence interval
MI 5 myocardial infarction
NQMI 5 non-Q wave myocardial infarction
TIMI 5 Thrombolysis in Myocardial Infarction
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and clinical outcomes was performed using the chi-square or
Fisher exact test for dichotomous variables and either the
Wilcoxon rank sum or the two-tailed t test for continuous
variables. Rapid assay results across patient groups distributed
by quintile of CRP concentration were compared by a one-way
analysis of variance. In an effort to identify those patients at
highest mortality risk, thresholds for the primary outcomes
analysis were set toward the extremes of CRP and cTnT
elevation (the 99th percentile of normal range for CRP and
early positive rapid cTnT assay results). A series of two-by-two
contingency tables for each test category (CRP $1.55 mg/dl,
rapid cTnT assay early positive and both conditions positive)
for the outcome of death at 14 days were constructed and the
sensitivity, specificity and likelihood ratio for each test deter-
mined. All statistical comparisons were two-tailed, and p
values ,0.05 considered statistically significant.
Results
Baseline characteristics. Of the 630 patients enrolled in
the TIMI 11A trial between July 1995 and January 1996, 437
(70%) had both a rapid cTnT assay and quantitative CRP
determined at least 6 h after symptom onset. Those who did
not have the requisite samples drawn and data reported for
this serum marker substudy did not differ significantly from
participants with respect to any of the baseline characteristics
collected, except that there were fewer patients reporting a
previous history of angina (62% vs. 74%, p 5 0.003) with a
concomitant decrease in the use of aspirin and intravenous
nitrates before enrollment.
CRP values ranged from 0.01 to 19.80 mg/dl (median 0.58;
25th and 75th percentiles 0.24 and 1.48 mg/dl, respectively).
Twenty-five percent of patients had a markedly elevated CRP
$1.55 mg/dl (99th percentile of healthy control values from the
core laboratory). These patients had baseline characteristics
similar to the remainder of the cohort, with few exceptions
(Table 1). Of note, previous examination of CRP in a large
patient group demonstrated no association between CRP
concentration and diabetes (18). Higher rates of intravenous
heparin and nitrate use may reflect the more serious clinical
condition consistent with the higher risk profile of the group
with elevated CRP.
Correlation with rapid troponin T. Of the 437 patients
included in the present substudy, 346 had a negative rapid
cTnT assay, and 43 of the remaining 91 patients had a positive
rapid cTnT assay with an early positive result. The probability
of a positive rapid cTnT assay increased with rising concentra-
tions of CRP (Fig. 1). However, even among those patients
with a negative rapid cTnT assay, a wide range of CRP
concentrations were observed, with a median of 0.51 mg/dl and
25th and 75th percentiles of 0.21 and 1.21 mg/dl, respectively.
Twenty percent of patients with a negative rapid cTnT assay
had CRP levels $1.55 mg/dl.
Correlation of serum markers with mortality at 14 days.
Mean CRP concentration at enrollment was elevated at 7.21
mg/dl in patients who subsequently died during the 14-day
follow-up period versus 1.29 mg/dl in survivors (p 5 0.0038).
The all-cause 14-day mortality rate for the study cohort was
1.6%. Mortality was significantly higher among patients with
CRP $1.55 mg/dl than in all others, and notably, this increase
in mortality was evident even among those with a negative
rapid cTnT assay (Fig. 2). Furthermore, among patients with a
positive rapid cTnT assay, the mortality rate in the group with
CRP ,1.55 mg/dl was 0% compared with 5.1% in those with
CRP above threshold. Stratifying by both CRP and rapid
cTnT, we found that patients with both an early positive rapid
cTnT assay (#10 min until assay positive) and CRP $1.55
mg/dl had the highest mortality, followed by those with either
CRP $1.55 mg/dl or an early positive rapid cTnT assay.
Patients with both a negative rapid cTnT assay and CRP ,1.55
mg/dl were at very low risk (p 5 0.0007) (Fig. 3).
A CRP level elevated to $1.55 mg/dl was a more sensitive
marker for increased mortality than was early positive cTnT
assay positivity (86% vs. 29%) while maintaining moderate
specificity (76% vs. 91%) (Fig. 4). Analysis of all positive rapid
cTnT assays shows a mortality rate of 2.2% for patients with a
positive test compared with 1.5% in those with a negative
result, with a corresponding sensitivity and specificity of 29%
and 79%, respectively. The combination of CRP and an early
positive rapid cTnT assay was the most specific indicator of
mortality at 95% and was associated with the highest likeli-
hood ratio for mortality at 6.1.
Table 1. Baseline Characteristics
Baseline Characteristic
CRP ,1.55 mg/dl
(n 5 329)
CRP $1.55 mg/dl
(n 5 108)
Mean age (yr) 62.1 62.9
Gender
Male 220 (67%) 60 (56%)*
Female 109 48
Race
White 264 (80%) 85 (79%)
Other 65 23
Diabetes 99 (30%) 47 (44%)*
Current smoker 89 (27%) 27 (25%)
Hypertension 196 (60%) 69 (64%)
Previous cardiac history
Angina 247 (75%) 78 (72%)
Previous angiogram with
stenosis $50%
194 (59%) 58 (54%)
PTCA 57 (17%) 14 (13%)
CABG 27 (8%) 17 (16%)*
MI 5 (2%) 2 (2%)
Medications before enrollment
ASA 274 (83%) 95 (88%)
IV nitrates 82 (25%) 43 (40%)*
Beta-blockers 164 (50%) 52 (48%)
IV heparin 168 (51%) 70 (65%)*
*Denotes categories for which p # 0.05. For continuous variables, the values
shown indicate the median; for dichotomous variables, the values indicate the
number (percent) of patients with a given finding. ASA 5 aspirin; CABG 5
coronary artery bypass graft surgery; IV 5 intravenous; MI 5 myocardial
infarction; PTCA 5 percutaneous transluminal coronary angioplasty.
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Discussion
The present analysis of serum markers drawn at enrollment
of patients with unstable angina and NQMI in the TIMI 11A
trial strongly suggests a prognostic role for CRP with respect to
short-term mortality in this cohort. In addition, the present
report demonstrates the combined prognostic value of an assay
for cTnT and CRP in stratifying patients for mortality risk.
Notably, among patients with a negative rapid bedside cTnT
assay, a markedly elevated CRP ($99th percentile for normal
control values in the core laboratory) identifies patients who
remain at significantly increased risk for death in the first 14
days and thus confers additional prognostic information above
cTnT results alone. Furthermore, we observed that using the
rapid cTnT assay and CRP in combination provided a more
comprehensive risk assessment with respect to mortality. Pa-
tients with unstable angina and NQMI compose a diverse
population with a broad range of risk for adverse clinical
outcomes (29,30). Thus, the ability to effectively risk stratify
patients at presentation should prove useful in triaging patients
to the appropriate level of hospital care as well as potentially
guiding clinical interventions.
Inflammation in coronary artery disease. Multiple lines of
investigation have converged to suggest a prominent role of
inflammation in acute coronary syndromes. Histologically,
atheromatous plaques obtained at autopsy have demonstrated
(31–33) the presence of inflammatory mononuclear cells with
foci of monocytes, macrophages and T lymphocytes in the
arterial wall. Anatomically, the most common site of plaque
rupture in acute coronary syndromes appears to occur in the
shoulder region, where inflammatory cells are most prominent
and might serve to compromise the integrity of the surround-
Figure 1. Correlation of rapid cTnT
assay results and CRP concentration
expressed as the percentage of cTnT
assay results reading positive by quin-
tiles of CRP concentration. Trend
was evaluated by chi-square test.
Mortality at 14 days is displayed by
CRP quintile.
Figure 2. Mortality rate at 14 days by CRP concentration (open
bars 5 ,1.55 mg/dl; solid bars 5 .1.55 mg/dl) in all patients and in
those with negative (neg) and positive (pos) rapid cTnT assays.
Statistical comparison made by Fisher exact test.
Figure 3. Risk stratification by CRP (mg/dl) and rapid assay status
expressed as 14-day mortality rate by CRP and rapid cTnT result. Early
positive rapid assays are those that could be read positive by #10 min.
Trend evaluated by chi-square test. Neg 5 negative; Pos 5 positive.
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ing connective tissue (34). Release of key cytokines, such as
interleukin-6, with resultant stimulation of hepatic production
of acute-phase reactants, has been shown (35,36) to occur in
acute coronary syndromes, even in the absence of evidence of
myocardial necrosis. Thus, the acute-phase reactants have
been proposed as potential indicators of underlying atheroscle-
rotic disease and “unstable” atheromatous lesions (9,37). The
fact that there are reliable, widely available assays to determine
the serum concentration of CRP, and that this concentration is
essentially entirely dependent on the rate of primary produc-
tion, renders CRP a particularly attractive candidate serum
marker for this purpose (38–41). With a view toward wide-
spread clinical applicability, the assay used for this protocol is
a highly sensitive, fully automated, commercially available
assay.
CRP and prognosis. Studies of both cross-sectional and
case-control design have supported the association between
CRP and symptomatic CAD, as well as demonstrating an
increased risk of cardiovascular morbidity and mortality with
higher concentrations of CRP. Mendall et al. (10) examined
388 men between 50 and 69 years of age recruited from general
practice registers in Great Britain and showed an odds ratio for
CAD of 1.55 (95% confidence interval [CI] 1.25 to 1.92) per
doubling of CRP concentration. The MRFIT Research Group
(16) documented an association between CRP and coronary
heart disease mortality over 17 years of follow-up in asymp-
tomatic persons with multiple risk factors with a relative risk of
2.8 (95% CI 1.4 to 5.4) between the fourth and first quartiles of
CRP concentration. In a recent study by Ridker et al. (15),
CRP was shown to be a predictor of increased risk for
subsequent major cardiac events for patients with no known
CAD. In addition, at least two prospective studies reflecting a
spectrum of patients with symptomatic CAD have been com-
pleted. In the first study to suggest the prognostic value of CRP
for short-term outcome, Liuzzo et al. (24) showed that in a
subgroup of 31 patients with severe unstable angina and no
evidence of myocardial necrosis by admission quantitative
cTnT, a serum CRP concentration .0.3 mg/dl (90th percentile
of normal distribution) was predictive of more frequent recur-
rent angina and exhibited associated trends toward higher
rates of revascularization, MI and death. Subsequently, the
European Concerted Action on Thrombosis and Disabilities
Study Group (18) reported a correlation between elevated
CRP and nonfatal MI or sudden cardiac death in .2,000
outpatients with stable and unstable angina followed prospec-
tively for an average of 2 years, with an odds ratio for these
events of 1.81 for patients in the highest quintile of CRP
relative to those in the first to fourth quintiles.
Conclusions. Our report extends these observations on the
prognostic value of CRP to short-term mortality in the acute
hospital setting and supports using a combination of CRP and
cTnT for a more comprehensive risk assessment in patients
with unstable angina and NQMI. In addition, these data
demonstrate CRP to perform with superior sensitivity and
comparable specificity to an assay for cTnT in the identifica-
tion of patients at risk for early mortality in acute coronary
syndromes. We recognize the potential limitations of examin-
ing this risk relation in a single cohort with relatively few
events. However, the present study offers provocative data that
suggest a powerful role for mortality risk stratification combin-
ing information from measurement of both CRP and cTnT.
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